背景:卵巢甲状腺肿(SO)是一种罕见的肿瘤,可能转变为卵巢甲状腺肿类癌(OSC)和/或恶性卵巢甲状腺肿(MSO),但是发病率,临床特征,和生存结果还没有很好的定义。
方法:我们对1980年至2022年在我院接受治疗的卵巢间质疾病患者进行了回顾性研究。SO的亚组分析,OSC,随后进行了MSO。
结果:在12,864例卵巢畸胎瘤患者的队列中,共发现275例(2.14%),在哪里SO,OSC,MSO占83.3%,12.0%,和4.7%的病例,分别。在年龄上没有显著差异,肿瘤大小,肿瘤标志物升高,三个亚组中的腹水。在最初的治疗中,除一名SO患者出现转移性疾病外,所有SO或OSC患者均患有FIGOI期疾病,10例MSO局限于卵巢,而其他3例患者有转移性疾病。2例SO患者分别在腹膜和前直肠系膜复发,尽管采用了不同的外科手术,但OSC患者均未出现肿瘤复发或死亡。5年无复发生存率为88.9%,MSO患者在诊断后9.5年仅有1例死亡。放射性碘疗法治疗效果满意,但是这些患者对化疗反应不佳。
结论:2.14%的卵巢畸胎瘤可以归类为SO,其中12.0%和4.7%的SO可能转变为OSC和MSO,重复地。即使在SO转化为OSC或MSO后,生存结果也很好。
结论:SO占卵巢畸胎瘤的2.14%,其中12.0%和4.7%的SO可能转变为OSC和MSO,分别,并有出色的生存结果。
Struma ovarii (SO) is a rare tumor and may transform into ovarian strumal carcinoid (OSC) and/or malignant struma ovarii (MSO), but the incidence, clinical characteristics, and survival outcomes have not been well defined.
We conducted a retrospective
study of patients with ovarian strumal diseases treated in the our hospital between 1980 and 2022. Subgroup analyses of SO, OSC, and MSO were subsequently performed.
A total of 275 cases (2.14%) were identified in a cohort of 12,864 patients with ovarian teratomas, where SO, OSC, and MSO accounted for 83.3%, 12.0%, and 4.7% of cases, respectively. There were no significant differences in age, tumor sizes, elevated tumor markers, and ascites among the three subgroups. At initial treatment, all patients with SO or OSC had FIGO stage I disease except one SO patient presenting metastatic disease, ten patients had MSO confined to the ovary, whereas other three patients had metastatic diseases. Two patients with SO respectively relapsed at peritoneum and anterior mesorectum, while none of the OSC patients presented tumor recurrence or death despite different surgical procedures employed. The 5-year recurrence-free survival rate was 88.9%, and only one death occurred at 9.5 years after diagnosis in patients with MSO. Radioiodine therapy showed satisfactory therapeutic efficacy, but these patients showed poor responses to the chemotherapy.
2.14% of ovarian teratoma could be classified as SO, of which 12.0% and 4.7% of SO may transform into OSC and MSO, repsectively. The survival outcomes were excellent even after SO transformed into OSC or MSO.
SO occupied 2.14% of ovarian teratoma, where 12.0% and 4.7% of SO may transform into OSC and MSO, respectively, and had excellent survival outcomes.